Sentences with phrase «of programs in action»

Quality - assurance assessments help document the progress of programs in action.

A perfect example of the program in action is the story of Saffire, a shy dog who shook and hid in the kennel but eventually warmed up outside of it.

Not exact matches

DACA recipients» fears are not unfounded — the same fear surfaced several years ago after the Obama administration in 2014 attempted to expand DACA and implement a program known as Deferred Action for Parents of Americans and Lawful Permanent Residents, which sought to shield from deportation the parents of American citizens or lawful permanent residents.

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Neytanyahu delivered a visual - heavy presentation Monday that claimed to prove Tehran secretly pursued developing nuclear weapons, in a bid to undermine support for the Joint Comprehensive Plan of Action (JCPOA), the 2015 agreement signed with six major world powers to curb its nuclear program in exchange for economic sanctions relief.

«We'll be working with the NTSB to make sure we understand the root cause, and any further actions we need to take in terms of maintenance or inspections we'll want to add to our program.»

The course provides detailed examples of monitoring in action, allows you to get an overview of the different social media monitoring tools available for use, and strategies for how you can use what you've learned and apply it to your own social media program.

On Jan. 10, he offered to support a Democratic goal — providing legal status to some 800,000 young, undocumented immigrants under the Deferred Action for Childhood Arrivals program — in exchange for money for the wall as part of down - to - the - wire negotiations for a short - term budget.

Use of Name and Likeness: By posting User Content on the online services, you consent to the recording, use and reuse by NBCUniversal, its licensees, successors and assigns, of your voice, actions, likeness, name, appearance, profile photograph, performance, biographical material, and any other identifying information, including, without limitation, any information contained in your User Content (collectively, «Personal Elements»), as used, edited, altered, fictionalized or modified by NBCUniversal, in its sole discretion, in any and all media now known or hereafter devised, throughout the world, in perpetuity, including, without limitation, in and in connection with NBCUniversal, or related Sites or online services, in and in connection with any television programs and other productions, and in and in connection with advertising, promotion and publicity.

In 2010, as the Federal Reserve continued its quantitative easing program, Buffett sent the government a «thank you note» (in the form of an op - ed) for its actions, rather than its paralysis or politicking, after the crisiIn 2010, as the Federal Reserve continued its quantitative easing program, Buffett sent the government a «thank you note» (in the form of an op - ed) for its actions, rather than its paralysis or politicking, after the crisiin the form of an op - ed) for its actions, rather than its paralysis or politicking, after the crisis.

According to The News & Observer, Wednesday's report «found a new culprit: the Academic Support Program for Student - Athletes... The report describes a fairly broad group of academic and athletic officials who knew about athletes getting better grades in classes that only required papers, yet taking little or no action.»

And then the real expense kicks in: They have to be carefully set up and programmed by experts to rapidly perform actions to precisions of one - hundredth of an inch, over and over again, without any variation.

This obsession with metrics has led to initiatives like affirmative action hiring programs set up by some of the biggest names in tech, which, unfortunately, have failed to perform as hoped.

The first blockbuster case on the court's calendar is Oct. 10, when the justices will hear argument in a fight over the University of Texas» affirmative action program.

• Last year GM CEO Mary Barra oversaw the launch of the Women in Action leadership development program.

The PCAOB said in its own statement that it «has cooperated with and appreciates the government's actions to preserve and reinforce the integrity of the PCAOB's regulatory oversight programs that protect investors who rely on the audits of public companies.»

The Bank of England cut interest rates on Thursday for the first time since 2009, revived its bond - buying program and said it would take «whatever action is necessary» to achieve stability in the wake of Britain's vote to leave the European Union.

«The Commission will not take adverse action on a license renewal application based upon the subjective determination of a listener or group of listeners that the station has broadcast purportedly inappropriate programming,» the FCC commissioners wrote in a recent decision challenging a local radio station license.

The deal in question is the Joint Comprehensive Plan of Action, an agreement reached between Iran and six world powers in 2015 that placed limits on Iran's nuclear program in exchange for sanctions relief.

Santos, 29, is one of the approximately 750,000 undocumented immigrants in the U.S. who are currently covered by President Barack Obama's Deferred Action for Childhood Arrivals program.

Cruz, who is white, was never a part of that program and was eventually expelled from school due to his actions, making it an unusual focus in the debate that has followed the shooting.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Bringing in close to $ 800 million in total sales over the course of a cookie season, the cookie program enables girls nationwide to think big as they take action in their communities on issues they're passionate about.

Perkins Loan cancellation is currently offered to volunteers in the Peace Corps or ACTION program, teachers, members of the U.S. armed forces, nurses or medical technicians, law enforcement, Head Start workers, child or family services workers, and professional providers of early intervention services.

The TARP (Troubled Asset Relief Program) program, the early US stress tests, and various actions to recapitalise troubled banks and dispose of poorly performing assets were all important in this Program) program, the early US stress tests, and various actions to recapitalise troubled banks and dispose of poorly performing assets were all important in this program, the early US stress tests, and various actions to recapitalise troubled banks and dispose of poorly performing assets were all important in this regard.

Program expenses were up only 0.4 per cent, as the ending of most of the stimulus spending in the Economic Action Plan and lower employment insurance benefits nearly offset increases in transfers to other levels of governments (spending in this area is largely set in legislation) and in elderly benefits.

Under the Canada Economic Action Plan the deficit will be eliminated by 2015 - 16; although total net public debt will have increased by $ 150 billion, the debt ratio will have declined to 33.0 per cent in 2015 - 16 and reach the government's target of 25 percent by 2019 - 20; program spending will fall to below 13 percent of GDP and will continue to fall thereafter; public sector jobs have been eliminated; and income and corporate taxes have been cut.

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

The new lawsuit against the Deferred Action for Childhood Arrivals program was assigned to the same judge who ruled for the challengers earlier, U.S. District Judge Andrew S. Hanen, who sits in the federal courthouse in the Texas border town of Brownsville.

The decline in direct program expenses was primarily attributable to lower other transfer payments (down $ 5.5 billion), due to the ending of various stimulus measures under the Economic Action Plan.

Thank goodness because there was more than enough in his previous budgets, including the proliferation of tax expenditures (which are really spending programs but delivered through the tax system), various initiatives included in the Economic Action Plan, among others).

He also said an accelerated program allows shareholders to see immediate action, which is «important to signal a higher degree of confidence in something shareholders care a great deal about.»

And those who wish to think about the government's responsibility and actions in the hurricane - damaged parts of Florida or Texas or Virgin Islands or Puerto Rico or Cuba or elsewhere in the Caribbean, this program is for you.

According to Bullard, «the DOL has laid out in detail written documentation examples of material conflicts of interest and the firm's program for mitigating them, which is a virtual roadmap — and also an evidentiary motherlode for bringing both arbitration claims and class actions against firms.»

On the fiscal side, in 2009 the Congress and Administration enacted the largest fiscal stimulus program in history and some of these fiscal actions were renewed (e.g., extended unemployment compensation benefits) and new initiatives undertaken (e.g., the payroll tax holiday) once it became clear that the recovery was faltering.

Many factors could cause BlackBerry's actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statements, including, without limitation: BlackBerry's ability to enhance its current products and services, or develop new products and services in a timely manner or at competitive prices, including risks related to new product introductions; risks related to BlackBerry's ability to mitigate the impact of the anticipated decline in BlackBerry's infrastructure access fees on its consolidated revenue by developing an integrated services and software offering; intense competition, rapid change and significant strategic alliances within BlackBerry's industry; BlackBerry's reliance on carrier partners and distributors; risks associated with BlackBerry's foreign operations, including risks related to recent political and economic developments in Venezuela and the impact of foreign currency restrictions; risks relating to network disruptions and other business interruptions, including costs, potential liabilities, lost revenues and reputational damage associated with service interruptions; risks related to BlackBerry's ability to implement and to realize the anticipated benefits of its CORE program; BlackBerry's ability to maintain or increase its cash balance; security risks; BlackBerry's ability to attract and retain key personnel; risks related to intellectual property rights; BlackBerry's ability to expand and manage BlackBerry ® World ™; risks related to the collection, storage, transmission, use and disclosure of confidential and personal information; BlackBerry's ability to manage inventory and asset risk; BlackBerry's reliance on suppliers of functional components for its products and risks relating to its supply chain; BlackBerry's ability to obtain rights to use software or components supplied by third parties; BlackBerry's ability to successfully maintain and enhance its brand; risks related to government regulations, including regulations relating to encryption technology; BlackBerry's ability to continue to adapt to recent board and management changes and headcount reductions; reliance on strategic alliances with third - party network infrastructure developers, software platform vendors and service platform vendors; BlackBerry's reliance on third - party manufacturers; potential defects and vulnerabilities in BlackBerry's products; risks related to litigation, including litigation claims arising from BlackBerry's practice of providing forward - looking guidance; potential charges relating to the impairment of intangible assets recorded on BlackBerry's balance sheet; risks as a result of actions of activist shareholders; government regulation of wireless spectrum and radio frequencies; risks related to economic and geopolitical conditions; risks associated with acquisitions; foreign exchange risks; and difficulties in forecasting BlackBerry's financial results given the rapid technological changes, evolving industry standards, intense competition and short product life cycles that characterize the wireless communications industry.

In the most recent development, NRF supports renewal of the Deferred Action of Childhood Arrivals program in order to avoid disruption of workplaces if employees who are participants in the program were to be deporteIn the most recent development, NRF supports renewal of the Deferred Action of Childhood Arrivals program in order to avoid disruption of workplaces if employees who are participants in the program were to be deportein order to avoid disruption of workplaces if employees who are participants in the program were to be deportein the program were to be deported.

We invest considerably in celebrating our teams through programs (such as weekly «SOULccolade») that reward hard work, creativity, resourcefulness and actions that embody the culture and spirit of our brand.

Cook spoke out in support of Dreamers, 250 of whom are Apple employees, earlier this month when the Trump administration announced its decision to end the Deferred Action for Childhood Arrivals (DACA) program.

Strong candidates will have 1 - 3 years of consulting, M&A, strategy, or corporate development experience out of a first - tier undergraduate program and find intrinsic reward in an unstructured environment where individuals define their roles, own their actions and have outsized impact.

Top technology companies have devoted lobbying dollars and dispatched their executives to the nation's capital in order to save the program, called Deferred Action for Childhood Arrivals, which benefits some of their employees.

The Enrollment Program also authorizes a superior court to have jurisdiction over enrollees by allowing it to «appoint a receiver, monitor, conservator, or other designated fiduciary or officer of the court for a defendant or the defendant's assets,» as well as authorizes the Commissioner of Business Oversight to «include in civil actions claims for ancillary relief, including restitution and disgorgement, on behalf of a person injured, as well as attorney's fees and costs, and civil penalties of up to $ 25,000» for up to four years after the purported violation occurred and «refer evidence regarding violations of the bill's provisions to the Attorney General, the Financial Crimes Enforcement Network of the United States Department of the Treasury, or the district attorney of the county in which the violation occurred, who would be authorized, with or without this type of a reference, to institute appropriate proceedings.»

And that poses its own problem: House Democratic leadership has been adamant that it won't agree to any spending measure that fails to address the fate of those enrolled in the Obama - era Deferred Action for Childhood Arrivals program.

François has written a regular investment column in the magazine «Les Affaires Plus» and has been interviewed by MSN Money and a number of television programs such as «Capital - Actions» on the RDI network.

I am writing in recognition of your work to support «Dreamers», including those young men and women who are part of the Deferred Action for Childhood Arrivals (DACA) program.

The Deferred Action for Childhood Arrivals program changed the lives of young people who came to the United States illegally as children in incredible ways — boosting high school graduation rates and college enrollment, while slashing teen births by a staggering 45 percent.

«I do think these retirement entities should do more coaching or mentoring because they all have great education programs and great content, and some of them have been in existence for 50, 60 years so they have a lot of data to mine, to show results and how actions can influence those things.»

When President Donald Trump announced the end of the Deferred Action for Childhood Arrivals (DACA) program in September, he said he was giving Congress six months to find a legislative solution that would allow the 690,000 young unauthorized immigrants currently protected from deportation under DACA to stay in the country legally.

The bill appears to be heading toward the finish line, though at least three other Republican senators remained publicly undecided on Friday, including Mike Lee of Utah, who has allied with Mr. Rubio in pressing for an expanded child credit, and Jeff Flake of Arizona, who has been trying to extract commitments from Republican leadership related to the Deferred Action for Childhood Arrivals, or DACA, program.

Francois has writen a regular investment column in the magazine «Les Affaires Plus» and has been interviewed by MSN Money and a number of television programs such as «Capital - Actions» on the RDI network.